Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Accumulated Expenses (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Accumulated Expenses for 7 consecutive years, with $18.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 30.53% to $18.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.3 million, a 30.53% increase, with the full-year FY2025 number at $18.3 million, up 30.53% from a year prior.
  • Accumulated Expenses was $18.3 million for Q4 2025 at Kymera Therapeutics, up from $11.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $27.5 million in Q4 2022 to a low of $2.3 million in Q2 2021.
  • A 5-year average of $15.2 million and a median of $15.0 million in 2024 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 687.22% in 2021, then tumbled 82.71% in 2023.
  • Kymera Therapeutics' Accumulated Expenses stood at $23.0 million in 2021, then increased by 19.72% to $27.5 million in 2022, then tumbled by 59.18% to $11.2 million in 2023, then grew by 24.95% to $14.0 million in 2024, then soared by 30.53% to $18.3 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Accumulated Expenses are $18.3 million (Q4 2025), $11.7 million (Q3 2025), and $7.5 million (Q2 2025).